| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008967521 |
| P356 | DOI | 10.1038/NATURE06868 |
| P698 | PubMed publication ID | 18418378 |
| P50 | author | Hermann-Josef Gröne | Q29997998 |
| Tamer Rabie | Q37378616 | ||
| Ruth Ganss | Q38545902 | ||
| P2093 | author name string | Bernd Arnold | |
| Günter J Hämmerling | |||
| Sylvia Kaden | |||
| Fabian Kiessling | |||
| Paul Rigby | |||
| Manfred Jugold | |||
| Juliana Hamzah | |||
| Hugo H Marti | |||
| Mitali Manzur | |||
| P2860 | cites work | Transformation of the microvascular system during multistage tumorigenesis | Q44575069 |
| Novel endothelial cell markers in hepatocellular carcinoma | Q46161399 | ||
| CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction | Q47644730 | ||
| Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma | Q47737854 | ||
| Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats | Q48365404 | ||
| Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. | Q53350643 | ||
| Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization | Q28285584 | ||
| Characterization of a novel mammalian RGS protein that binds to Galpha proteins and inhibits pheromone signaling in yeast | Q28306561 | ||
| Cellular regulation of RGS proteins: modulators and integrators of G protein signaling | Q28646133 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| High interstitial fluid pressure - an obstacle in cancer therapy | Q29619719 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging | Q32068644 | ||
| Pericytes: cell biology and pathology | Q34243347 | ||
| Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors | Q35788785 | ||
| Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. | Q35791370 | ||
| Mini-review: overcoming tumor-intrinsic resistance to immune effector function. | Q35887878 | ||
| Genes that distinguish physiological and pathological angiogenesis | Q36087324 | ||
| PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival | Q37407269 | ||
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. | Q40031362 | ||
| Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen | Q40124763 | ||
| A Culture Device Demonstrates that Hydrostatic Pressure Increases mRNA of RGS5 in Neuroblastoma and CHC1-L in Lymphocytic Cells | Q40632428 | ||
| Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal | Q40848490 | ||
| Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model | Q42573981 | ||
| Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. | Q42629066 | ||
| P433 | issue | 7193 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 410-414 | |
| P577 | publication date | 2008-04-16 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Vascular normalization in Rgs5-deficient tumours promotes immune destruction | |
| P478 | volume | 453 |
| Q39632022 | A Dendritic Cell Population Generated by a Fusion of GM-CSF and IL-21 Induces Tumor-Antigen–Specific Immunity |
| Q34973743 | A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor |
| Q92195300 | A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer |
| Q34682173 | A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. |
| Q33889221 | A unifying hypothesis for scleroderma: identifying a target cell for scleroderma |
| Q34468330 | AAV2-mediated in vivo immune gene therapy of solid tumours |
| Q45378265 | Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer |
| Q39315901 | Alterations in metabolism-related genes induced in SHSY5Y cells by okadaic acid exposure. |
| Q37830361 | Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy |
| Q26774312 | Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches |
| Q30399006 | Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia |
| Q47370386 | Antiangiogenic effects of recombinant human endostatin in lung cancers. |
| Q38132055 | Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature |
| Q26740812 | Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis |
| Q38682453 | Autophagy, a double-edged sword in anti-angiogenesis therapy |
| Q33996674 | BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice |
| Q34719688 | Beta-agonist-associated reduction in RGS5 expression promotes airway smooth muscle hyper-responsiveness. |
| Q37726368 | Biology and functions of the RGS9 isoforms |
| Q34673567 | Biomarkers of response and resistance to antiangiogenic therapy |
| Q33382708 | Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas |
| Q82372171 | Brain pericytes: emerging concepts and functional roles in brain homeostasis |
| Q37502702 | Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. |
| Q27002903 | Broad targeting of angiogenesis for cancer prevention and therapy |
| Q47126472 | CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression |
| Q36389628 | Cancer therapeutic potential of combinatorial immuno- and vasomodulatory interventions |
| Q37768336 | Cellular and molecular aspects of vascular dysfunction in systemic sclerosis |
| Q37192031 | Changes in striatal signaling induce remodeling of RGS complexes containing Gbeta5 and R7BP subunits |
| Q36078893 | Characterization of arginylation branch of N-end rule pathway in G-protein-mediated proliferation and signaling of cardiomyocytes |
| Q35237477 | Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. |
| Q65556504 | Chloroquine and nanoparticle drug delivery: A promising combination |
| Q33752236 | Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis |
| Q38497294 | Combined effects of pericytes in the tumor microenvironment |
| Q34782683 | Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models |
| Q38447992 | Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? |
| Q38697147 | Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2-mediated angiogenesis |
| Q91621466 | Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants |
| Q26799117 | Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment |
| Q37683575 | Control of the adaptive immune response by tumor vasculature |
| Q27004733 | Control of the immune response by pro-angiogenic factors |
| Q47119535 | Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. |
| Q37254877 | DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature |
| Q47822985 | De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. |
| Q42696952 | Dendritic cell-targeted vaccines--hope or hype? |
| Q33757106 | Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice |
| Q33980128 | Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells. |
| Q38734283 | Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization |
| Q35650874 | Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells |
| Q36831553 | Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. |
| Q34470585 | Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor |
| Q41945623 | Effects of Feijining Decoction on vascular endothelial growth factor protein expression and changes of T cell subsets in Lewis lung carcinoma-bearing mice |
| Q37106787 | Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression |
| Q82437538 | Efficient Treg depletion induces T-cell infiltration and rejection of large tumors |
| Q38034448 | Emerging biotechnological strategies for non-viral antiangiogenic gene therapy |
| Q33745284 | Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. |
| Q37489539 | Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. |
| Q43413284 | Endothelial plasticity governs the site-specific leukocyte recruitment in hepatocellular cancer |
| Q37687429 | Enhancing adoptive immunotherapy of cancer. |
| Q38690566 | Environmental Enrichment Induces Pericyte and IgA-Dependent Wound Repair and Lifespan Extension in a Colon Tumor Model |
| Q52948211 | Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. |
| Q36261472 | Epigenetic Alterations Affecting Transcription Factors and Signaling Pathways in Stromal Cells of Endometriosis |
| Q92479136 | Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors |
| Q87827392 | Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer |
| Q55358544 | Fever-Inspired Immunotherapy Based on Photothermal CpG Nanotherapeutics: The Critical Role of Mild Heat in Regulating Tumor Microenvironment. |
| Q39406918 | Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. |
| Q28115604 | Focal DNA copy number changes in neuroblastoma target MYCN regulated genes |
| Q38019412 | Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. |
| Q45935444 | Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. |
| Q57178844 | Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease |
| Q33940693 | Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer |
| Q27320839 | Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes |
| Q43119907 | Good and bad news for an antiangiogenic |
| Q24329023 | HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF |
| Q37704659 | Hallmarks of cancer: interactions with the tumor stroma. |
| Q90455901 | Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling |
| Q30579125 | Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization |
| Q35237485 | Hiding the road signs that lead to tumor immunity |
| Q38805749 | Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. |
| Q39885086 | Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth |
| Q37872644 | How tumors might withstand γδ T-cell attack. |
| Q42144023 | Hypoxia promotes tumor growth in linking angiogenesis to immune escape |
| Q35369944 | IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells |
| Q41701383 | Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity |
| Q30941105 | Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy |
| Q28072147 | Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity |
| Q57791068 | Immune regulation of metastasis: mechanistic insights and therapeutic opportunities |
| Q53743967 | Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies. |
| Q38608340 | Immunological hallmarks of stromal cells in the tumour microenvironment |
| Q49592831 | Immunotherapeutic Targeting of Tumor-Associated Blood Vessels |
| Q38413904 | Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some |
| Q30492935 | Implanted microvessels progress through distinct neovascularization phenotypes |
| Q42549680 | Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning |
| Q42143399 | Implication of stem cells in the biology and therapy of head and neck cancer |
| Q89602909 | Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges |
| Q50051034 | Improving immune-vascular crosstalk for cancer immunotherapy. |
| Q50055217 | Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa |
| Q89626915 | Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies |
| Q52583527 | Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. |
| Q29617534 | Influence of tumour micro-environment heterogeneity on therapeutic response |
| Q37352000 | Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. |
| Q26830418 | Intertwined regulation of angiogenesis and immunity by myeloid cells |
| Q34757171 | Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens |
| Q41767601 | Intratumoral TNFα improves immunotherapy. |
| Q36285953 | Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer |
| Q45067616 | KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis |
| Q36871777 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity |
| Q57823139 | Loss of Regulator of G-Protein Signaling 5 Leads to Neurovascular Protection in Stroke |
| Q34137610 | Loss of regulator of G protein signaling 5 exacerbates obesity, hepatic steatosis, inflammation and insulin resistance |
| Q40421152 | Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection |
| Q38098095 | MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response |
| Q93333207 | Microvascular Mural Cells in Cancer |
| Q27004093 | Microvascular repair: post-angiogenesis vascular dynamics |
| Q38254639 | Molecular insights into the development of T cell-based immunotherapy for prostate cancer |
| Q37328406 | Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth |
| Q45866445 | Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. |
| Q55347856 | Non-Invasive Radiofrequency Field Treatment of 4T1 Breast Tumors Induces T-cell Dependent Inflammatory Response. |
| Q30471456 | Normalization of the vasculature for treatment of cancer and other diseases |
| Q30542073 | Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers |
| Q97532341 | Novel Immunotherapeutic Approaches in Head and Neck Cancer |
| Q39123733 | Over-expression of regulator of G protein signaling 5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma cells |
| Q30425676 | PDGF-dependent regulation of regulator of G protein signaling-5 expression and vascular smooth muscle cell functionality |
| Q34191687 | PDGFRβ signaling regulates mural cell plasticity and inhibits fat development. |
| Q33749460 | Pancreatic cancer: pathobiology, treatment options, and drug delivery |
| Q35125382 | Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant |
| Q38769098 | Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse |
| Q30418921 | Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy |
| Q92421246 | Pericytes in Breast Cancer |
| Q91866976 | Pericytes in Cerebrovascular Diseases: An Emerging Therapeutic Target |
| Q92421258 | Pericytes in Metastasis |
| Q92151830 | Pericytes in Microvessels: From "Mural" Function to Brain and Retina Regeneration |
| Q36695062 | Pericytes on the tumor vasculature: jekyll or hyde? |
| Q37852794 | Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy |
| Q38582873 | Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment |
| Q50050444 | Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin |
| Q42187650 | Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity |
| Q39650152 | Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model |
| Q37883025 | Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases |
| Q97418387 | Prostaglandin E2 breaks down pericyte-endothelial cell interaction via EP1 and EP4-dependent downregulation of pericyte N-cadherin, connexin-43, and R-Ras |
| Q30596824 | RGS expression in cancer: oncomining the cancer microarray data |
| Q37358126 | RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells |
| Q27307762 | Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration |
| Q38728953 | Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma |
| Q37726377 | Regulation of immune function by G protein-coupled receptors, trimeric G proteins, and RGS proteins. |
| Q57254079 | Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia |
| Q34068533 | Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload |
| Q36075974 | Regulator of G-Protein Signaling 5 Reduces HeyA8 Ovarian Cancer Cell Proliferation and Extends Survival in a Murine Tumor Model. |
| Q35823514 | Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment |
| Q91642168 | Regulator of G-protein signaling 5 regulates the shift from perivascular to parenchymal pericytes in the chronic phase after stroke |
| Q36342101 | Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice |
| Q37726354 | Regulators of G protein signaling proteins as central components of G protein-coupled receptor signaling complexes |
| Q37778514 | Regulators of G protein signaling proteins as targets for drug discovery. |
| Q34198530 | Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets |
| Q34354756 | Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma |
| Q46586252 | Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice. |
| Q37016995 | Remodeling of tumor stroma and response to therapy |
| Q35256189 | Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth |
| Q42640884 | Rethinking cancer nanotheranostics |
| Q64266519 | Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment |
| Q40619105 | Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells |
| Q37403111 | Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models |
| Q37055402 | Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication |
| Q41816171 | Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy |
| Q36497233 | Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice |
| Q51687761 | Spinal cord injury repair by implantation of structured hyaluronic acid scaffold with PLGA microspheres in the rat. |
| Q34384193 | Suppression of glioma progression by Egln3 |
| Q28259872 | T cell exclusion, immune privilege, and the tumor microenvironment |
| Q29248893 | Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy |
| Q35006442 | Targeting microvasculature for neuroprotection after SCI |
| Q38805897 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy |
| Q33920350 | Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. |
| Q26742168 | Tertiary Lymphoid Organs in Cancer Tissues |
| Q34021937 | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia |
| Q37947993 | The N-end rule pathway: emerging functions and molecular principles of substrate recognition |
| Q37690651 | The Pleiotropic Role of L1CAM in Tumor Vasculature |
| Q37516448 | The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment |
| Q58754484 | The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy |
| Q27025579 | The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities |
| Q58561576 | The clinical role of the TME in solid cancer |
| Q36555524 | The determinants of tumour immunogenicity |
| Q36998535 | The dual effect of mesenchymal stem cells on tumour growth and tumour angiogenesis |
| Q37351606 | The head and neck cancer immune landscape and its immunotherapeutic implications |
| Q38028791 | The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies |
| Q54239507 | The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. |
| Q41577994 | The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms |
| Q36879125 | The vasculature: a vessel for bone metastasis. |
| Q35161285 | Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. |
| Q36085091 | Tissue resident regulatory T cells: novel therapeutic targets for human disease |
| Q33560685 | Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors |
| Q33765767 | Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors |
| Q38001321 | Tumor microenvironment and lymphocyte infiltration |
| Q33811126 | Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models |
| Q40577362 | Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. |
| Q37798176 | Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology |
| Q35974293 | Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. |
| Q60926323 | Tumour vessel normalization and immune checkpoint blockade: a new synergism |
| Q99408892 | Tumour vessel remodelling: new opportunities in cancer treatment |
| Q47276645 | Ultrahigh-Resolution Optical Coherence Elastography Images Cellular-Scale Stiffness of Mouse Aorta |
| Q27005794 | Understanding high endothelial venules: Lessons for cancer immunology |
| Q90106416 | VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models |
| Q35740182 | Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice |
| Q26827437 | Vascular normalization and cancer immunotherapy |
| Q30469815 | Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. |
| Q36847357 | Vascular normalization as an emerging strategy to enhance cancer immunotherapy |
| Q42414835 | Vascular normalization in cerebral angiogenesis: friend or foe? |
| Q36378276 | Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy |
| Q38126351 | Vascular remodeling in cancer. |
| Q39024164 | Vessel pruning or healing: endothelial metabolism as a novel target? |
| Q43170327 | Visualizing anti-tumor immune responses in vivo |
| Q101403153 | ZNF354C is a transcriptional repressor that inhibits endothelial angiogenic sprouting |
Search more.